The company positions itself at the intersection of personalized medicine and preventative healthcare, utilizing its proprietary Health Data Platform to detect risks for multiple chronic diseases. Nightingale connects healthcare providers with individuals seeking preventative services, operating through both in-person and remote health check models.
Cyborg Score Rationale
Despite innovative technology in health diagnostics, Nightingale faces significant challenges: negative EBITDA of €-9.86M, minimal trailing 12-month revenue of $5.1M, analyst consensus rating of 'Strong Sell', and substantial underperformance relative to market benchmarks over six months. The company remains unprofitable with negative EPS forecasts.
Top Insights
Proprietary blood analysis technology measures broad biomarkers from single sample, differentiating from competitors in disease risk detection
Currently unprofitable with significant negative EBITDA (-€9.86M) and minimal revenue ($5.1M TTM), indicating commercialization challenges
Stock classified as 'Sucker Stock' by analysts with 'Strong Sell' consensus and target price €1.80 (10% below current trading level)
Early employee count of ~86-95 employees suggests pre-scaling phase with substantial growth investments required to reach profitability
Named Competitors
GeneDx Holding — Genetic diagnostics and interpretation
Truvian — Rapid diagnostic testing platform
Lark — Digital preventative health coaching
Recent Developments
(Jan 2023) Acquired blood self-collection device technology from Weavr Health (Velvet device)
(2025) Company maintained operations across expanded geographic footprint including Japan, Singapore, and Nordic expansion
Open the full interactive Nightingale Health Oyj report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.